Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use
R Teschke, G Danan - International Journal of Molecular Sciences, 2023 - mdpi.com
Clinical and mechanistic considerations in idiosyncratic drug-induced liver injury (iDILI)
remain challenging topics when they are derived from mere case narratives or iDILI cases …
remain challenging topics when they are derived from mere case narratives or iDILI cases …
Immune checkpoint inhibitor-induced liver injury
In recent years cancer treatment has been revolutionized by the development and wide
application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI …
application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI …
Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors
L Shojaie, JM Bogdanov, H Alavifard… - Cell Death & …, 2024 - nature.com
Abstract Immune checkpoints (CTLA4 & PD-1) are inhibitory pathways that block aberrant
immune activity and maintain self-tolerance. Tumors co-opt these checkpoints to avoid …
immune activity and maintain self-tolerance. Tumors co-opt these checkpoints to avoid …
[HTML][HTML] Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors
L Parlati, M Sakka, A Retbi, S Bouam, L Hassani… - JHEP Reports, 2023 - Elsevier
Background & Aims There is concern about the burden of liver injury in patients with cancer
exposed to immune checkpoints inhibitors (ICIs). Methods In a retrospective cohort study, we …
exposed to immune checkpoints inhibitors (ICIs). Methods In a retrospective cohort study, we …
Beyond the lungs: Exploring diverse applications of bromhexine and ambroxol
The respiratory tract is commonly affected in multisystem disorders. Although many drugs
have been developed to target various components of these diseases, there is still a need …
have been developed to target various components of these diseases, there is still a need …
Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the …
Z Fu, J Liu, C Zhang, H Hu, S Li, Y Zhang… - Frontiers in …, 2024 - frontiersin.org
Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1 and anti-
CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However …
CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However …
Idiosyncratic DILI and RUCAM under one hat: The global view
R Teschke, G Danan - Livers, 2023 - mdpi.com
Drugs are prescribed worldwide to treat diseases but with the risk of idiosyncratic drug-
induced liver injury (iDILI). The most important difficulty is how best to establish causality …
induced liver injury (iDILI). The most important difficulty is how best to establish causality …
Fever of unknown origin associated with immune checkpoint inhibitors
X Tong, T Zhan, X Dong, D Xu - Frontiers in Immunology, 2024 - frontiersin.org
Since the approval for the treatment of melanoma in 2014, immune checkpoint inhibitors
(ICIs) have revolutionized the therapy pattern across various malignancies. Coinciding with …
(ICIs) have revolutionized the therapy pattern across various malignancies. Coinciding with …
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
M Yue, C Li, G Li - International Immunopharmacology, 2024 - Elsevier
The application of immune checkpoint inhibitors (ICIs) has made extraordinary
achievements in tumor treatment. Among them, programmed cell death protein 1 (PD …
achievements in tumor treatment. Among them, programmed cell death protein 1 (PD …
The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management
A Lasagna, P Sacchi - Cancers, 2024 - mdpi.com
Simple Summary Immune-mediated hepatotoxicity (IMH) is a not-so-rare complication of
immune checkpoint inhibitors (ICIs) and it is extremely heterogeneous in its clinical …
immune checkpoint inhibitors (ICIs) and it is extremely heterogeneous in its clinical …